ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to with your member or guest account, and visit the subscription center available under your account profile.

June 12, 2024

Bipartisan members of the Unites States House of Representatives and Senate have reintroduced the Association for Clinical Oncology (ASCO)-endorsed Improving Seniors’ Timely Access to Care Act (H.R.8702/S.4518) to streamline prior authorization within Medicare Advantage (MA) plans. Last Congress, this legislation had 380 combined cosponsors—53 senators and 327 representatives—and was unanimously passed by the House before stalling in the Senate.  


June 4, 2024

The American Society of Clinical Oncology (ASCO) hosted a panel discussion focused on finding solutions to the crisis of cancer drug shortages at the 2024 ASCO Annual Meeting. The session, “Solving Decades of Drug Shortages in Oncology: What, Who, and When?,” featured experts to review potential market/economic factors that can improve resiliency in the sterile injectable drug market and potential policy changes to help mitigate future shortages.

June 4, 2024

ASCO held a media briefing on June 2, 2024, with NCI Director W. Kimryn Rathmell, MD, PhD, FASCO, who sat down with ASCO Medical Director Julie Gralow, MD, FACP, FASCO.

June 3, 2024

In recognition of its exceptional advocacy efforts, the Society of Utah Medical Oncologists received the 2023 Jeffery C. Ward Affiliate Advocacy Award during Annual Meeting.

May 31, 2024

The American Society of Clinical Oncology (ASCO) released, “Principles for the Responsible Use of Artificial Intelligence in Oncology,” to guide ASCO’s consideration of all aspects of artificial intelligence (AI). With this manuscript, the Society joins colleagues across medicine in offering principles that should be applied in development and implementation of AI. The principles are offered as a framework to help the oncology community safely use AI to the benefit of patients and the clinicians who care for them.

May 30, 2024

On May 30, 2024, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor (BTKi).

May 29, 2024

On May 29, 2024, the Food and Drug Administration granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for pediatric patients two years of age and older with specific needs. 

May 21, 2024

Congressional committees and subcommittees recently made progress toward extending the telehealth flexibilities for Medicare services that were established during the COVID-19 Public Health Emergency. This activity follows the 2024 Advocacy Summit, during which volunteer advocates from the Association for Clinical Oncology were on Capitol Hill urging Congress to permanently extend these flexibilities.

May 21, 2024

The Association for Clinical Oncology (ASCO) is urging lawmakers to continue their bipartisan support for federal cancer research in Fiscal Year (FY) 2025.

May 20, 2024

On May 20, 2024, the FDA Oncology Center of Excellence (OCE) announced the formation of The OCE Equity Program. The new program expands Project Equity, continuing the Oncology Center’s work to improve access to clinical trials of oncology medical products for populations that have been historically underrepresented in clinical research.

May 17, 2024

The American Cancer Society (ACS) and American Society of Clinical Oncology (ASCO) are hosting the webinar, Oncology Navigation: Elevating Care Quality and the Patient Experience, on May 23.

May 16, 2024

On May 16, 2024, the Food and Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. 

May 15, 2024

On May 15, 2024, the Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy.

May 7, 2024

The Department of Health and Human Services Office for Civil Rights and the Centers for Medicare & Medicaid Services issued a final rule under Section 1557 of the Affordable Care Act (ACA) advancing protections against discrimination in health care. This long-awaited regulation restores the full scope of ACA’s section 1557 non-discrimination protections on the basis of sex, gender identity, or pregnancy status, after the scope of the protections had been limited by the previous administration.

May 7, 2024

On May 2, the Centers for Medicare & Medicaid Services finalized a rule expanding access to health care coverage for Deferred Action for Childhood Arrivals (DACA) recipients. Beginning November 1, 2024, DACA recipients will be eligible to enroll in a Qualified Health Plan through the Affordable Care Act Health Insurance Marketplace, or for coverage through a Basic Health Program.